PURPOSE: While a clear heritable component underlies lower urinary tract symptoms and benign prostatic hyperplasia, few studies have identified specific genetic factors. In contrast, recent genome-wide association studies identified single nucleotide polymorphisms that increase prostate cancer risk. Some of these single nucleotide polymorphisms may also predispose to surgical intervention for benign prostatic hyperplasia. We determined whether these single nucleotide polymorphisms are also associated with lower urinary tract symptom severity and benign prostatic hyperplasia medication use. MATERIALS AND METHODS: The genotypes of 38 single nucleotide polymorphisms previously associated with prostate cancer risk were determined for 1,168 healthy white male volunteers. American Urological Association symptom index score and medication for benign prostatic hyperplasia were documented prospectively. Statistical analyses were done to compare the frequency of the single nucleotide polymorphisms with American Urological Association symptom index and benign prostatic hyperplasia medication use. RESULTS: Several single nucleotide polymorphisms, including rs2736098 on chromosome 5p15, showed a significant relationship with benign prostatic hyperplasia medication. After adjusting for the other genetic variants, patient age and medication use, rs1571801 on chromosome 9q33.2 (OR 1.31, 95% CI 1.0-1.74) and rs5945572 on chromosome Xp11 (OR 1.28, 95% CI 1.04-1.59) were significantly associated with increased urinary symptoms. In contrast, rs445114 on chromosome 8q24 was marginally associated with decreased urinary symptoms (OR 0.83, 95% CI 0.66-1.01). CONCLUSIONS: Of 38 single nucleotide polymorphisms that predispose to prostate cancer we identified 3 that are also associated with a well characterized lower urinary tract symptom phenotype. These single nucleotide polymorphisms may aid in the improved characterization of men with lower urinary tract symptoms/benign prostatic hyperplasia.
PURPOSE: While a clear heritable component underlies lower urinary tract symptoms and benign prostatic hyperplasia, few studies have identified specific genetic factors. In contrast, recent genome-wide association studies identified single nucleotide polymorphisms that increase prostate cancer risk. Some of these single nucleotide polymorphisms may also predispose to surgical intervention for benign prostatic hyperplasia. We determined whether these single nucleotide polymorphisms are also associated with lower urinary tract symptom severity and benign prostatic hyperplasia medication use. MATERIALS AND METHODS: The genotypes of 38 single nucleotide polymorphisms previously associated with prostate cancer risk were determined for 1,168 healthy white male volunteers. American Urological Association symptom index score and medication for benign prostatic hyperplasia were documented prospectively. Statistical analyses were done to compare the frequency of the single nucleotide polymorphisms with American Urological Association symptom index and benign prostatic hyperplasia medication use. RESULTS: Several single nucleotide polymorphisms, including rs2736098 on chromosome 5p15, showed a significant relationship with benign prostatic hyperplasia medication. After adjusting for the other genetic variants, patient age and medication use, rs1571801 on chromosome 9q33.2 (OR 1.31, 95% CI 1.0-1.74) and rs5945572 on chromosome Xp11 (OR 1.28, 95% CI 1.04-1.59) were significantly associated with increased urinary symptoms. In contrast, rs445114 on chromosome 8q24 was marginally associated with decreased urinary symptoms (OR 0.83, 95% CI 0.66-1.01). CONCLUSIONS: Of 38 single nucleotide polymorphisms that predispose to prostate cancer we identified 3 that are also associated with a well characterized lower urinary tract symptom phenotype. These single nucleotide polymorphisms may aid in the improved characterization of men with lower urinary tract symptoms/benign prostatic hyperplasia.
Authors: Jean-Nicolas Cornu; Etienne Audet-Walsh; Sarah Drouin; Pierre Bigot; Antoine Valeri; Georges Fournier; Abdel-Rahmène Azzouzi; Morgan Roupret; Luc Cormier; Stephen Chanock; Chantal Guillemette; Olivier Cussenot; Eric Lévesque; Géraldine Cancel-Tassin Journal: World J Urol Date: 2016-06-08 Impact factor: 4.226
Authors: Daniel Reinhardt; Brian T Helfand; Phillip R Cooper; Kimberly A Roehl; William J Catalona; Stacy Loeb Journal: J Urol Date: 2013-12-15 Impact factor: 7.450
Authors: Rufus Cartwright; Altaf Mangera; Kari A O Tikkinen; Prabhakar Rajan; Jori Pesonen; Anna C Kirby; Ganesh Thiagamoorthy; Chris Ambrose; Juan Gonzalez-Maffe; Phillip R Bennett; Tom Palmer; Andrew Walley; Marjo-Riitta Järvelin; Vik Khullar; Chris Chapple Journal: Eur Urol Date: 2014-01-22 Impact factor: 20.096
Authors: Julius Gudmundsson; Jon K Sigurdsson; Lilja Stefansdottir; Bjarni A Agnarsson; Helgi J Isaksson; Olafur A Stefansson; Sigurjon A Gudjonsson; Daniel F Gudbjartsson; Gisli Masson; Michael L Frigge; Simon N Stacey; Patrick Sulem; Gisli H Halldorsson; Vinicius Tragante; Hilma Holm; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Isleifur Olafsson; Thorvaldur Jonsson; Eirikur Jonsson; Rosa B Barkardottir; Rafn Hilmarsson; Folkert W Asselbergs; Gudmundur Geirsson; Unnur Thorsteinsdottir; Thorunn Rafnar; Gudmar Thorleifsson; Kari Stefansson Journal: Nat Commun Date: 2018-11-08 Impact factor: 14.919